Revenue: As of FY2025 Q1, the actual value is USD 9.167 M.

EPS: As of FY2025 Q1, the actual value is USD -0.39.

Segment Revenue

• Revenue: $9,167 thousand for the three months ended March 31, 2025, compared to $6,457 thousand for the same period in 2024, representing a 42.0% increase.

Operational Metrics

• Gross Profit: $7,672 thousand for the three months ended March 31, 2025, compared to $5,486 thousand for the same period in 2024.
• Gross Margin: 83.7% for the three months ended March 31, 2025, compared to 85.0% for the same period in 2024.
• Loss from Operations: - $7,329 thousand for the three months ended March 31, 2025, compared to - $11,672 thousand for the same period in 2024.
• Net Loss: - $10,375 thousand for the three months ended March 31, 2025, compared to - $13,206 thousand for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $4,499 thousand for the three months ended March 31, 2025, compared to - $10,867 thousand for the same period in 2024.
• Net Cash Used in Investing Activities: - $714 thousand for the three months ended March 31, 2025, compared to - $66 thousand for the same period in 2024.
• Net Cash Provided by Financing Activities: $9,688 thousand for the three months ended March 31, 2025, compared to $3,126 thousand for the same period in 2024.

Unique Metrics

• Undeclared Dividends on Series A Preferred Stock: - $712 thousand for the three months ended March 31, 2025, compared to - $801 thousand for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the commercialization of TriNav and expand its PEDD device portfolio with the TriNav LV Infusion System and TriGuide Guiding Catheter, targeting larger vessel sizes.
• Non-Core Business: TriSalus is exploring partnerships for further clinical development of nelitolimod, following Phase I trials.
• Priority: The company aims to achieve a trailing 12-month Product Revenue Base of $50 million by December 31, 2025, to access additional funding under the OrbiMed Credit Agreement.